GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cardax CDXI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cardax

Its shares trade under the ticker CDXI. It has been listed since 30 January 2012. In the fiscal year to 31 December 2020, it reported revenue of $538,946 and a net loss of $5.1m. At that date it held total assets of $1.4m and shareholders' equity of −$10.2m.

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii. The company went IPO on 2012-01-30. The company seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. The company intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
30 Jan 2012
Employees
10

Leadership

Pay as last reported

  • Mr. David WatumullChairman of the Board, President, Chief Executive Officer, since 2014$214,957
  • Mr. David WatumullChief Financial Officer, Chief Operating Officer, Assistant Treasurer, Company Secretary$162,108

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cardax employs only ten full-time staff members.
  • The company holds proprietary astaxanthin prodrug technology.
  • CDX-101 targets cardiovascular inflammation and dyslipidemia.

Weaknesses

  • The firm is in the development stage with no products on the market.
  • Both candidates CDX-101 and CDX-301 remain pre-clinical.
  • Monetization of its pharmaceutical candidates has not yet occurred.

Opportunities

  • CDX-301 targets the macular degeneration market.
  • Zeaxanthin accumulation offers protection against oxidative damage.
  • Astaxanthin supports metabolic and joint health benefits.

Threats

  • Competitors may develop superior anti-inflammatory treatments.
  • Regulatory hurdles exist for pre-clinical pharmaceutical candidates.
  • Market adoption depends on successful clinical trial outcomes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.